A 43-year-old HIV-positive Ethiopian immigrant presented with persistent diarrhoea, hepatosplenomegaly and pancytopaenia. Visceral leishmaniasis was diagnosed by multiple gastrointestinal tract biopsies. Blood polymerase chain reaction (PCR) was positive for Leishmania donovani. Despite highly active antiretroviral therapy (HAART) and multiple courses of antileishmanial treatments, including liposomal amphotericin and sodium stibogluconate, the patient had multiple relapses. CD4 counts remained at 40–60 cells/µL although viral loads were undetectable. Splenectomy resulted in resolution of the patient's pancytopaenia and in rising CD4 levels, which enabled a long-lasting remission.
PintadoV, Martin-RabadanP, RiveraML, MorenoS, BouzaE. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore)2001;80:54–73
2.
GuerinPJ, OlliaroP, SundarS, Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis2002;2:494–501
3.
del GiudiceP, Mary-KrauseM, PradierC, Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis2002;186:1366–70
4.
BerenguerJ, MorenoS, CercenadoE, Bernaldo de QuirosJC, Garcia de la FuenteA, BouzaE. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med1989; 111:129–32
5.
DesjeuxP, AlvarJ. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol2003;97(Suppl 1):3–15
6.
AlvarJ, CanavateC, Gutierrez-SolarB, Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev1997;10:298–319
7.
Gonzalez-AngladaMI, PenaJM, BarbadoFJ, Two cases of laryngeal leishmaniasis in patients infected with HIV. Eur J Clin Microbiol Infect Dis1994;13:509–11
8.
ClevenberghP, OkomeMN, BenoitS, Acute renal failure as initial presentation of visceral leishmaniasis in an HIV-1-infected patient. Scand J Infect Dis2002;34:546–47
9.
DuarteMI, da MattaVL, CorbettCE, LaurentiMD, ChebaboR, GotoH. Interstitial pneumonitis in human visceral leishmaniasis. Trans R Soc Trop Med Hyg1989;83:73–76
10.
LagunaF, Garcia-SamaniegoJ, MorenoV, Gonzalez-LahozJM. Prevalence of gastrointestinal leishmaniasis in Spanish HIV-positive patients with digestive symptoms. Am J Gastroenterol1994;89:1606
11.
RosenthalE, MartyP, del GiudiceP, HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis2000;31:1093–95
12.
de La RosaR, PinedaJA, DelgadoJ, Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol2002;40:762–67
13.
LagunaF, Lopez-VelezR, PulidoF, Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS1999;13:1063–69
14.
BernC, Adler-MooreJ, BerenguerJ, Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis2006;43:917–24
15.
MeyerhoffA. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis1999;28:42–8;discussion 49–51
16.
MishraJ, SaxenaA, SinghS. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem2007;14:1153–69
17.
SundarS, JhaTK, ThakurCP, SinhaPK, BhattacharyaSK. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med2007;356:2571–81
18.
JhaTK, SundarS, ThakurCP, Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med1999;341:1795–800
19.
RitmeijerK, MelakuY, MuellerM, KipngetichS, O'KeeffeC, DavidsonRN. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med Hyg2006;74:76–80
20.
Lopez-VelezR, VidelaS, MarquezM, Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother2004;53:540–43
21.
MolinaI, FalcoV, CrespoM, Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother2007;60:837–42
22.
RiberaE, OcanaI, de OteroJ, CortesE, GasserI, PahissaA. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med1996;100:496–501
23.
TroyaJ, CasqueroA, MunizG, Fernandez-GuerreroML, GorgolasM. The role of splenectomy in HIV-infected patients with relapsing visceral leishmaniasis. Parasitology2007;134:621–24
